Get the Stockscreener App
7.52
2.87%
0.21
After Hours:
7.52
Nuvectis Pharma Inc stock is traded at $7.52, with a volume of 72,170.
It is up +2.87% in the last 24 hours and down -16.26% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$7.31
Open:
$7.43
24h Volume:
72,170
Relative Volume:
0.54
Market Cap:
$188.46M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-5.3333
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-2.84%
1M Performance:
-16.26%
6M Performance:
+39.52%
1Y Performance:
+15.51%
1-Day Range:
$7.32
$7.59
1-Week Range:
$7.25
$8.055
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.52 | 188.46M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha
Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Yahoo Finance
Insider Stock Buying Of Nuvectis Pharma Delivers Return On US$2.19m Investment - simplywall.st
Nuvectis Pharma Approves Proposals at Annual Meeting - TipRanks
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Sold by Two Sigma Investments LP - Defense World
Millennium Management LLC Reduces Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Investment Analysis - news.stocktradersdaily.com
Squarepoint Ops LLC Invests $103,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Northern Trust Corp - Defense World
(NVCT) On The My Stocks Page - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Invests $34,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire
Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India
Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World
Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World
Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks
Nuvectis Pharma launches public stock offering - MSN
(NVCT) Investment Report - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks
Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times
Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq
Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan
Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World
(NVCT) Trading Signals - news.stocktradersdaily.com
Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st
SCHD ETF News, 4/14/2025 - The Globe and Mail
Top 5 Small-cap Pharma Stocks in 2025 - Investing News Network
When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):